918642-61-2

Usage

Uses

Used in Pharmaceutical Industry:
Cyclopropanecarboxylic acid, 1-[[(2-fluorophenyl)amino]carbonyl]-, is used as a key intermediate in the synthesis of 1,1-cyclopropyl diamide derivatives. These derivatives possess significant biological activity and are valuable for the development of new pharmaceutical agents with potential therapeutic applications.
In the preparation of 1,1-cyclopropyl diamide derivatives, Cyclopropanecarboxylic acid, 1-[[(2-fluorophenyl)amino]carbonyl]-, plays a crucial role in providing the necessary structural framework and functional groups that contribute to the overall activity and efficacy of the final compounds. This makes it an important component in the ongoing research and development of novel therapeutic agents in the pharmaceutical industry.

Upstream product

• 40258-99-9 1-(chlorocarbonyl)cyclopropane-1-carboxylic acid 
• 348-54-9 2-Fluoroaniline 
• 598-10-7 cyclopropane-1,1-dicarboxylic acid 

Downstream Products

• 928038-27-1 [4-(3-fluoro-4-{[1-(2-fluorophenylcarbamoyl)cyclopropanecarbonyl]amino}phenoxy)pyridin-2-yl]-N-(phenoxycarbonyl)carbamic acid phenyl ester 

Relevant academic research and scientific papers

Preparation and applications for novel 1,1-cyclopropyl diamide derivative

The invention discloses preparation and applications for a novel 1,1-cyclopropyl diamide derivative, and relates to a novel 1,1-cyclopropyl diamide derivative having a formula (I) and a salt thereof,including a medicinal salt, wherein R1, R2, R3, R4 and R

Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate

A series of novel hybrid structure derivatives, containing both LEE011 and Cabozantinib pharmacophore, were designed, synthesized and evaluated. Surprisingly, a compound 4d was discovered that highly exhibited effective and selective activity of CDK9 inhi

N3-Arylmalonamides: A new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases

A family of thieno[3,2-b]pyridine based small molecule inhibitors of c-Met and VEGFR2 were designed based on lead structure 2. These compounds were shown to have IC50 values in the low nanomolar range in vitro and were efficacious in human tumo

NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3)

A compound represented by the following formula, a salt thereof or a hydrate of the foregoing has an excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity and cancer metastasis inhibitory activity. [R1 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; R2 and R3 represent hydrogen; R4, R5, R6, and R7 may be the same or different and each represents hydrogen, halogen, C1-6 alkyl or the like; R8 represents hydrogen or the like; R9 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; n represents an integer of 1 or 2; X represents -CH=, nitrogen or the like.]

Inhibitors of VEGF receptor and HGF receptor signaling

The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions